Development and validation of an ELISA at acidic pH for the quantitative determination of IL-13 in human plasma and serum.
A novel sandwich ELISA for the quantitative and sensitive determination of IL-13 in human serum and plasma was established. The assay employs an incubation step at acidic pH, which was shown to decrease nonspecific binding and interference from IL-13 binding proteins. The assay was validated and was shown to be accurate and precise over the entire quantification range (0.59 to 68.4 pg/mL in human EDTA plasma). The validated assay was successfully applied to samples from healthy volunteers and patients with atopic seasonal rhinitis. The assay is suitable for use in clinical trials to monitor efficacy or pharmacodynamic effects of drug candidates.
Department of Marker Localization and Assays, Biomarker Development, Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland.
Julie
J
Doucet
An
A
Zhao
Jean
J
Fu
Alexandre
A
Avrameas
D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007159:Immunologic Tests / Q000379:methods*; D018793:Interleukin-13 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D006255:Rhinitis, Allergic, Seasonal / Q000097:blood / Q000175:diagnosis; D012680:Sensitivity and Specificity
D018793:Interleukin-13